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Abstract
Background: We tested the feasibility of delivering and evaluating a complex therapy intervention which aimed to
promote activity and independence for people with early dementia (PrAISED). Feasibility questions were on:
recruitment, randomisation, intervention delivery, adherence and withdrawals, level of supervision required, adverse
events, data collection and sample size assumptions.
Methods: We conducted a three-arm, multi-site, single-blind, randomised controlled feasibility trial. Eligibility criteria
were aged 65 years or older, diagnosed mild dementia or mild cognitive impairment, able to walk without human
help, and communicate in English, no co-morbidities that prevented participation in cognitive assessment and
capacity to give consent. Participants were recruited from Memory Assessment Service clinics and the ‘Join
Dementia Research’ register.
Patient participants were randomised 1:1:1 to a high intensity supervision PrAISED intervention, moderate intensity
supervision PrAISED intervention or brief falls prevention assessment and advice (control). The PrAISED intervention
aimed for participants to complete three hours of PrAISED exercises a week for 12 months. It included
individualised activity and exercise plans and supervised exercises with regular re-assessment and progression, and
was delivered by occupational therapists, physiotherapists and rehabilitation support workers. Primary efficacy
outcome was the Disability Assessment for Dementia (DAD), measured after 12 months. Secondary outcomes
included physical activity, quality of life, mood, cognition, strength, balance, rate of falls, frailty and carer strain. Falls
and activity were ascertained by monthly diary.
Results: Between September 2016 and March 2017 we recruited 60 patient participants and 54 carer participants
from two sites. Forty-nine patient participants completed a follow-up interview. Feasibility outcomes were mostly
satisfactory, including recruitment and retention, intervention delivery and data completeness for most scales used.
We could not maintain blinding of researchers at follow-up and experienced difficulties collecting data using some
questionnaires and devices. Participants only completed a mean 77 (moderate supervision) and 71 (high
supervision) minutes per week of PrAISED exercises over 12 months. We recorded 19 adverse events, none serious
and related to the intervention.
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Conclusion: We conclude that with some adjustments to the trial protocol, it is feasible to deliver the PrAISED
intervention and conduct a trial.
Trial registration: ClinicalTrials.gov: NCT02874300 (first posted 22nd August 2016), ISRCTN: 10550694 (date
assigned 31st August 2016).
Keywords: Dementia, Therapeutic exercise, Activities of daily living, Randomised controlled trial, Occupational
therapy, Physiotherapy, Falls
Background
Dementia comprises a group of progressive neurological
diseases that affect memory and other cognitive functions,
and which are severe enough to restrict daily function.
Mild Cognitive Impairment (MCI) is a potential precursor
state, with measurable cognitive deficits, but preserved
functional ability, which progresses to dementia in over
half of cases [1]. Neuropsychological deficits and falls risks
are similar in people living with both diagnoses [2].
Remaining independent is a priority for people living with
dementia and their carers [3, 4]. Ability to perform activ-
ities of daily living (ADL) deteriorates as the disease
progresses. This is partly due to worsening cognitive im-
pairment, including memory, apraxia, agnosia and execu-
tive function, but other aspects also contribute, including
deconditioning, co-morbidities or injuries, failure to com-
pensate or adapt to cognitive loss, and over-protectiveness
or restriction of opportunity by carers, often in the name
of safety. People living with dementia are especially prone
to falls, physical illness, delirium, other crises and deterior-
ation whilst in hospital.
A multi-disciplinary rehabilitation approach can ad-
dress some of the problems. Physiotherapy aims to sup-
port activity through increases in strength and balance,
improving gait, fitness, and confidence and reducing the
risk of falls. Occupational therapy can support independ-
ence through cognitive rehabilitation and risk enable-
ment approaches. Health psychology can support the
individual to make changes to their daily life to become
more active by linking these desired changes to basic
psychological needs, and addressing barriers.
A Cochrane systematic review [5] reported evidence
that exercise programs for people with dementia improved
ADL, but the quality of evidence was rated as poor. High
intensity home-based exercise reduced rate of loss of
ADLs and falls [6], and functionally-directed home-based
therapy can also increase activity [7], although this has not
been replicated [8]. Many other trials of simple interven-
tions in dementia have failed to improve outcomes; for ex-
ample, a moderate intensity group exercise programme
failed to improve cognition or ADL [9]. The optimum
‘dose’ of exercise required to improve ADLs in people
with dementia is not clear; most studies aimed for one
hour of exercise three times a week for 24 weeks [5],
which is similar to the amount of exercise required to re-
duce risk of falls. The World Health Organisation (WHO)
recommend that people aged 65 years and older with poor
mobility should do balance challenging exercise on 3 or
more days a week and muscle strengthening activities on
two more days [10]. Inconsistency in trial results may be
due to variable or low intervention adherence, ranging
from 16 to 100% in a review [unpublished observation
from Di Lorito, C. Bosco, A. Booth, V. Goldberg, S. Har-
wood R.H. and van der Wardt, V.].
We systematically developed a complex intervention
which aims to keep people living with early dementia or
mild cognitive impairment independent and active,
whilst reducing their risk of falls, and focusing on pro-
moting uptake and adherence [11]. The intervention was
developed over five years [4, 11, 12], by a team including
occupational- and physio-therapists, health psycholo-
gists, nurses, geriatricians and carer representatives.
Feasibility trials are increasingly used to test trial
methods, the practicality of delivering the intervention,
and parameters needed to plan recruitment and estimate
sample size, in advance of conducting a fully-powered
randomised controlled trial. Methods for designing, and
interpreting feasibility studies and responding to their
findings have been published [13–15].
Methods
Study design
We undertook a pragmatic, parallel group, single-blinded,
randomised controlled feasibility trial at two study sites,
recruiting from Memory Assessment Services (dementia
diagnostic services) and the Join Dementia Research regis-
ter, a United Kingdom National Institute for Health
Research (NIHR) web-based initiative to increase partici-
pation in dementia research [16]. The full rationale and
protocol have been published [17]. There were no signifi-
cant changes to the research plan during the feasibility
study. The CONSORT 2010 checklist of information to
include when reporting a pilot or feasibility trial is avail-
able in Additional file 1.
Participants
Patient participants were identified by clinicians working
in Memory Assessment Services and referred to the
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research team if interested, or by researchers through
the Join Dementia Research Register. We included
patient participants who were age 65 years or over and
had diagnosed mild dementia or mild cognitive impair-
ment (Montreal Cognitive Assessment (MoCA) score of
15–25 [18]; Mini Mental State Examination (MMSE) of
18–26 [19] or Addenbrookes Cognitive Examination III
(ACEIII) 60–94 [20], depending on what assessments
clinics used). Patient participants had to be able to walk
without human assistance and communicate in English,
have no co-morbidities that prevented participation in
cognitive assessment and capacity to give informed con-
sent (formally assessed by a researcher). A family mem-
ber or informal carer of the patient participant who
could communicate in English was recruited, if willing.
Written consent was taken from both patient and carer
participants. We chose to study people with mild impair-
ments as our intervention was designed to prevent or
slow decline amongst those still well enough to engage
and learn new lifestyle activities.
Researchers and NIHR Clinical Research Network
clinical support officers (CSO) recruiting patient partici-
pants and collecting data had two days training in study
procedures. Two researchers or CSOs visited the patient
and carer participants in their own home to complete a
screening questionnaire, discuss the study and take writ-
ten informed consent. The commitment needed to
complete the study (if randomised to one of the active
arms) was emphasised to avoid later withdrawals. Base-
line data were collected from the patient and carer par-
ticipant. Some patient participant data were collected
from the carer participant to reduce burden. Visits with
two researchers or CSOs allowed the patient and carer
participants to be interviewed concurrently in different
rooms, reducing the overall time of the interview and
allowing the participants to respond freely.
To describe the patient participants, we collected
demographic data, past medical history, medications,
and falls risk factors from the carer participant and mea-
sured cognition by completing a standardised mini men-
tal state examination (sMMSE) [19] with the patient
participant.
The intervention
We tested two versions of the PrAISED intervention,
which differed in the amount of professional supervision
offered. Both versions aimed for the patient participant
to complete three hours of PrAISED exercises each week
for the 12month intervention period. Both versions in-
cluded assessment, creation of an individualised tailored
exercise and activity plan, supervised exercises and activ-
ity, and regular reassessments and progression. Patient
participants in the high intensity supervision group
received up to 50 visits from a therapist or rehabilitation
support worker (RSW) over a period of one year. Patient
participants in the moderate intensity supervision group
received 9 visits from a therapist (or two therapists for
initial assessment visits) and three phone calls over a
three month period, and encouragement to continue the
programme after professional supervision ceased.
The PrAISED physical exercises included balance
challenging, strength building, dual-task training and
gait re-education. Some exercises could be gained
through functional strategies which aimed to maintain
or improve independence. Patient participants in the
high intensity supervision group received visits that
were tapered over the year, starting at twice weekly for
three months, then weekly for three months, bi-
monthly for three months and monthly for the last
three months. Patient participants in the moderate in-
tensity supervision group received tapered visits in the
first three months of the twelve month intervention
period. The supervision regimens were based on prece-
dents from the literature [6, 21]. Both interventions in-
cluded motivational strategies to encourage adherence
to, and persistence with, the planned exercises and ac-
tivities. Participants were encouraged to continue their
exercise and activities beyond the supervised period
and were provided information on appropriate com-
munity exercise groups in their area. Therapists and
RSWs delivering the intervention received three days
training prior to the start of the study and 2 days train-
ing during the intervention delivery period. The con-
trol group had a single falls prevention assessment and
advice with one to two follow-up visits by a therapist if
indicated. Standard care controls are common practice
in activity and exercise interventions for people with
dementia [6, 9, 21].
Objectives
A feasibility study aims to answer the question “can this
study be done?” [22]. They play an important role in the
subsequent design of a fully powered trial [13]. Specific
trial feasibility questions were [17]:
i) Can we recruit and randomise patient participants
at a sufficient rate (set at > 2.5 participants per week
from 2 sites)?
ii) Can we deliver the intervention across sites and in
patient participants’ homes?
iii) Is the intervention adhered to and how many
withdraw (Set at > 75% of participants retained in
the study)?
iv) What level of supervision intensity is required that
will enable engagement at a level likely to be
effective?
v) Are there any unexpected or adverse consequences?
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vi) Can we collect blinded trial data at baseline and
follow- up without burdening participants (set at
< 20% missing primary outcome)?
vii) Are our sample size assumptions correct?
Health status outcomes
Outcomes were measured at baseline and 12month
follow-up visits.
Activities of daily living were measured using the Dis-
ability Assessment for Dementia scale (DAD) [23], com-
pleted by the carer participant and the Nottingham
Extended Activities of Daily Living Scale (NEADL) [24],
completed by patient participant.
Cognition was measured using Cambridge Neuro-
psychological Test Automated Battery (CANTAB) tests
[25, 26]: Paired Associated Learning (PAL), Attention
Switching Task (AST), Spatial Working Memory (SWM).
We also measured a verbal fluency test (from MoCA)
[18]. We used these tests as previous studies had shown
that it was unlikely that exercise would improve global
cognition scores, but may influence specific elements such
as executive function. The clinical dementia rating [27]
was completed by the researcher.
Sitting and standing blood pressure and pulse rate
were measured using an automated sphygmomanometer
(Omron, Milton Keynes, UK). The Berg Balance Scale
[28], leg and hand strength (Lafayette dynamometer,
Loughborough, UK), timed up and go (TUG) test and
dual task TUG (whilst counting backwards in 3’s) were
measured directly with the patient participant. The
SHARE Frailty instrument [29], and International Phys-
ical Activity Questionnaire (IPAQ) [30] were completed
by carer participant.
Quality of life was measured from the patient partici-
pant using EQ-5D-3L [31]; and Dementia Quality of Life
Scale (Demqol) [32]. Demqol proxy was completed by
the carer participant. Anxiety and depression (Hospital
Anxiety and Depression Scale, HADS) [33] and Falls Ef-
ficacy Scale – International (FES-I) [34] were completed
by the patient participant. Carer participants completed
the carer strain index (CSI) [35].
Throughout the year of follow-up, patient participants
were asked to complete and return monthly falls and
exercise calendars, by post, in a stamped addressed enve-
lope provided by the researchers or CSOs, prompted by
monthly telephone reminders. At baseline, six and 12
months patient participants were asked to wear and then
return, by post, a tri-axial accelerometer for one week to
objectively measure activity. A range of accelerometers
were provided to participants. See Table 1 for data
collection time points.
Adverse events were monitored and reported to the
principal investigator at each site by therapists, RSWs
and researchers during telephone contacts to prompt
diary return. Adverse events were defined as hospitalisa-
tion, or incidents which were life threatening, causing
persistent or significant disability or incapacity, or an in-
cident, injury or symptom related to therapy sessions or
exercise undertaken independently.
Randomisation
Participants were randomly allocated to one of the three
arms, stratified by site, presence of a co-resident carer
and history of previous falls (to control for confounding
variables) using a dynamic adaptive allocation algorithm
[36] accessed by a secure web portal held at the
NWORTH clinical trials unit (CTU), Bangor University.
The randomisation system was maintained by a statisti-
cian independent of the analysis and research teams to
ensure blinding of analysis. The researchers and CSOs
entered the patient participant’s details into the web por-
tal. Notification of allocation was sent to ‘unblinded’
members of the research team who notified the thera-
pists of allocation. The therapists then informed the pa-
tient participant. Patient participants were randomised 1:
1:1 to high intensity supervision, moderate intensity
supervision or standard falls prevention assessment and
advice (the control arm).
Concealment
We could not blind the patient and carer participants to
the intervention. We took measures to ensure the re-
searchers collecting primary outcome data were blind to
allocation. For example, the ‘blinded’ researchers sat in a
different office, spreadsheets identifying allocation were
password protected to avoid accidentally seeing alloca-
tions and we took care in meetings not to reveal alloca-
tion. Randomisation emails giving details on allocation
were not sent to ‘blinded’ researchers.
Data management
Data were entered into a MACRO database. Data which
could ‘unblind’ researchers was kept separately from
‘blinded’ data on MACRO with access given as appropri-
ate. Database management and data cleaning were man-
aged by the CTU. Source data verification was
undertaken for 5% of data from both carers and patient
participants at baseline and follow-up at each site.
Source data to be verified were randomly selected by the
CTU and researchers completed the verification checks.
Sample size calculation
A sample size of 60 was chosen to be sufficient to an-
swer feasibility questions. A sample of this size would
give adequate precision using a confidence interval ap-
proach [37] which considers the likelihood of a future
definitive study finding a relevant effect size.
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Statistical analysis
A statistical analysis plan was drawn up by the trial stat-
istician prior to completion of recruitment. Statistical
analyses provided descriptive statistics on recruitment
and retention rates, participation, missing data, adverse
events, follow-up, and falls ascertainment rates, and the
distributions of key variables required for main trial
sample size calculation. Mean health status variables
were calculated by group, at baseline and follow-up, with
mean differences. Standardised effect size estimates from
analyses of covariance (ANCOVA), equivalent to
Cohen’s d [38], were calculated. A Cohen’s d of 0.2 to
0.5 is a small effect size; 0.5 to 0.8 is a medium effect
size and greater than 0.8 is a large effect size [38].
Progression to trial
We set discontinuation rules of recruitment (> 2.5 par-
ticipants per week), retention (> 77%), intervention set
up at sites, data collection (< 20% missing primary
outcome).
Results
Recruitment and randomisation rate
Between September 2016 and March 2017 371 people
with mild dementia or MCI were referred to the study
and 201 were pre-screened. Of these, 52 were ineligible
and 86 either not interested or lost. We screened the
remaining 63, one was ineligible and two withdrew. We
recruited 60 patient participants and 54 carer partici-
pants, on schedule (consort diagram, Fig. 1). Seventeen
were recruited via Join Dementia Research. Patient par-
ticipants had a mean age of 76 years (range 65–91), 34/
60 (57%) were male and 45/60 (75%) married. Most were
white ethnicity (58/60, 97%); lived with another person
(48/60, 80%); had received secondary education 32/60
(53%) and many had received further education 26/60
(43%). Mean sMMSE was 25.6/30 (range 18–30), 55/59
(93%) had a diagnosis of dementia. Carer participants
were younger with a mean age of 68 years (range 33–
87), 45/60 (75%) were spouses and 39/60, (65%) were fe-
male (Table 2). Twenty one patient participants were
randomised to standard care, nineteen to the moderate
intensity supervision intervention and twenty to the high
intensity supervision intervention. There was a gender
imbalance between groups with 62% of the standard care
group being female compared to 37 and 30% in the
moderate and high intensity supervision groups; groups
were otherwise well-matched at baseline.
Intervention delivery
The intervention was successfully delivered in partici-
pant’s homes, across the two sites with the control group
Table 1 Data collection time points
Scale or measure Baseline 6 months 12 months Completed by
Disability in dementia scale (DAD) X X Carer participant
Nottingham Extended Activities of Daily Living Scale (NEADL) X X Patient participant
Demographics X Carer participant
Past Medical History X Carer participant
Medications X Carer participant
Falls risk factors X Carer participant
Standardised Mini Mental State Examination (sMMSE) X Patient participant
Verbal fluency X X Patient participant
Cambridge Neuropsychological Test Automated Battery (CANTAB) tests X X Patient participant
Blood pressure and pulse X X Patient participant
Berg Balance scale X X Patient participant
Leg and hand strength X X Patient participant
Timed up and go test and dual task timed up and go test. X X Patient participant
SHARE frailty instrument X X Patient participant
International Physcial Activity Questionnaire (IPAQ) X X Carer participant
EQ-5D-3L X X Patient participant
Dementia Quality of Life Scale (Demqol) X X Patient participant
Hospital Anxiety and Depression Scale (HADS) X X Patient participant
Falls Efficacy Scale – International (FES-I) X X Patient participant
Carer strain index X X Carer participant
Steps (accelerometer) X X X Patient participant
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receiving a mean of 2 sessions, the moderate intensity
supervision group receiving 12/12 (100%) sessions
(including telephone calls) and the high intensity super-
vision group receiving 33/50 (66%) sessions, although
some sessions had more than one therapist attending.
Adherence and withdrawal
Three hundred and ninety one out of five hundred and
twenty eight (74%) of the exercise and falls calendars
were returned. From these calendars, mean PrAISED
related physical activity minutes per week for both inter-
vention groups was 72min (Standard deviation (SD) =
63) when calculated for the time between baseline and
follow up (approximately 11 months). In the moderate
intensity supervision group, participants completed a
mean of 77 min (SD = 71; range 15 to 228 min) per week
and 71min (SD = 56; range 11 to 246 min) in the high
intensity supervision group. Those in the control group
had not been given PrAISED exercises to complete.
Seven participants withdrew from therapy before the 12
month outcome visit (three from the high intensity super-
vision group, two from the moderate intensity supervision
group and two from the control group). Two participants
gave depression as the reason for withdrawing, one was
feeling overwhelmed, one felt he wasn’t eligible because
he was physically well, one thought it was the wrong time
and that the visits stopped her going out and doing what
she wanted to do, one withdrew due to physical and men-
tal deterioration and one withdrew due to bereavement
and feeling the exercises were not appropriate to her age
due to risk of falls.
Data collection and blinding
Between September 2017 and March 2018, 49/60 (82%)
participants completed the follow-up visit with nine
withdrawals and two participants lost to follow-up. 16/
21 (76%) participants from the control group completed
the follow up visit, 15/19 (79%) from the moderate
Fig. 1 Consort diagram
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intensity supervision group and 18/20 (90%) from the
high intensity supervision group. Assessment interviews
proved lengthy with a median duration of 115 min. 32/
52 (62%) patient participants reported that the time
taken was acceptable 16/52 (31%) considering that it was
too long. Missing data at baseline and follow-up varied
across the different measures and questionnaires (Table
3). The primary outcome measure, the DAD, was com-
pleted for 52/60 (87%) participants at baseline and 46/49
(94%) participants at follow-up. DAD is an informant
rated scale. Six participants were recruited without a
carer, so did not provide DAD data. A ceiling effect was
seen with 11/52 participants at baseline and 4/46 at
follow-up gaining full scores on the DAD. CANTAB
assessments and accelerometer data showed consider-
able missing data due to technical problems. The carer
participants reported finding the IPAQ difficult to
complete.
Despite efforts to blind researchers collecting follow-up
data the researchers were able to correctly identify alloca-
tion (intervention or control) for 42/49 (86%) outcome
visits.
Supervision intensity required to enable engagement
There was a trend towards better performance on the
primary outcome measure, DAD, and less deterioration
from baseline, with higher intensity supervision. Mean
DAD scores were 76/100 at baseline versus 58/100 at
follow-up for the control group, 83 versus 66 for the
moderate intensity supervision group and 76 versus 68
for the high intensity group. Cohen’s d was 0.03 (− 0.7 to
0.8) for moderate (no effect) and 0.43 (− 0.3 to 1.2) for
high intensity supervision (a small effect size), compared
with control (Tables 3 and 4) [38].
The Berg Balance Scale showed a large and statistically
significant positive effect size for the moderate intensity
d = 0.9, 95% CI [0.1, 1.8] and high intensity d = 1.0, 95%
CI [0.1, 1.8] groups compared with control. Fear of fall-
ing improved for the moderate intensity supervision
group d = − 0.8, 95% CI [− 1.7, − 0.03] (Table 4).
Unexpected or adverse outcomes
There were 19 recorded adverse events. Five were re-
lated to the intervention but not serious, 12 were ser-
ious but not related, 2 were neither serious nor
related to the intervention. They were all recorded in
the active intervention groups, but were subject to as-
certainment bias as these groups had much more
contact with therapists.
Only 12 falls were reported by participants over the
12months, fewer than anticipated [2, 17]. The incident
rate ratios (IRR) were 0.68, (95% CI 0.16, 2.8) and 1.20,
Table 2 Distribution of participant categorical demographic variables split by the allocation group
Standard falls prevention
N = 21
Moderate-intensity supervision
N = 19
High-intensity supervision
N = 20
Total n/N (%)
Patient Participants
Gender Female n (%) 13 (62%) 7 (37%) 6 (30%) 26/60 (43%)
Marital Status Married n (%) 16 (76%) 14 (74%) 15 (75%) 45/60 (75%)
Ethnic Group White n (%) 20 (95%) 18 (95%) 20 (100%) 58/60 (97%)
First Language English n (%) 20 (95%) 19 (100%) 20 (100%) 59/60 (98%)
Living Alone n (%) 5 (24%) 4 (21%) 3 (15%) 12/60 (20%)
sMMSE mean/30 (sd) 25.9 (2.4) 24.8 (3.6) 26.2 (3.2) 25.6 (3.1)
Diagnosed dementia 19/20 (95%) 18/19 (95%) 18/20 (90%) 55/59 (93%)
Education
Primary school education or less 0 (0%) 1 (5%) 0 (0%) 1/60 (2%)
Secondary education 11 (52%) 11 (58%) 10 (50%) 32/60 (53%)
Further education 9 (43%) 7 (37%) 10 (50%) 26/60 (43%)
Not Answered 1 (5%) 0 (0%) 0 (0%) 1/60 (2%)
CARER PARTICIPANTS
Carer Relationship with Person in Study
Husband/wife/partner 15 (71%) 15 (79%) 15 (75%) 45/60 (75%)
Son/daughter 3 (14%) 3 (16%) 3 (15%) 9/60 (15%)
No carer recruited 3 (14%) 1 (5%) 2 (10%) 6/60 (10%)
Carer Gender Female 10 (48%) 13 (68%) 16 (80%) 39/60 (65%)
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Table 3 Crude scores on oncome measures according to randomisation group for the PrAISED feasibility study
Measure Group N Baseline
Mean (SD)
Follow-up
Mean (SD)
Difference Interpretation
DAD Score/100 Control 14 76 (20) 58 (33) −18 deterioration
Moderate 15 83 (17) 66 (30) −17 deterioration
High 15 76 (25) 68 (25) −8 deterioration
NEADL Score/22 Control 10 16 (4) 15 (6) −1 deterioration
Moderate 13 17 (5) 15 (5) −1 deterioration
High 17 16 (5) 15 (5) −1 deterioration
DEMQoL /112 Control 13 85 (18) 86 (20) 1 improvement
Moderate 14 88 (8) 91 (15) 3 improvement
High 17 86 (16) 86 (16) 0 unchanged
DEMQoL Proxy/124 Control 15 91 (15) 92 (15) 1 improvement
Moderate 15 98 (14) 101 (13) 3 improvement
High 16 91 (15) 94 (18) 2 improvement
Berg Balance Scale/56 Control 11 49 (9) 43 (17) −7 deterioration
Moderate 13 52 (2) 52 (3) −1 deterioration
High 13 50 (10) 50 (6) 0 unchanged
Falls Efficacy Scale-International/64 Control 12 28 (11) 34 (15) 6 deterioration
Moderate 13 25 (13) 23 (11) −2 improvement
High 13 23 (8) 25 (12) 2 deterioration
IPAQ Physical Activity Score* Control 12 1456 (1466) 989 (1187) − 467 deterioration
Moderate 14 2489 (2464) 1323 (923) − 1166 deterioration
High 14 1484 (1658) 1729 (1873) 245 improvement
HADS Anxiety/21 Control 11 5.2 (3.7) 4.8 (4.9) −0.4 improvement
Moderate 13 6.5 (3.3) 4.5 (2.4) −2.0 improvement
High 14 6.2 (4.0) 7.0 (4.4) 0.8 deterioration
HADS Depression/21 Control 11 4.4 (3.7) 3.7 (3.0) −0.6 improvement
Moderate 11 4.0 (3.6) 3.3 (2.0) −0.7 improvement
High 15 4.8 (3.9) 4.7 (3.0) −0.1 improvement
SHARE Frailty Index (no maximum score) Control 14 1.5 (1.7) 1.9 (2.0) 0.4 deterioration
Moderate 14 0.6 (1.6) 0.4 (1.4) −0.2 improvement
High 14 1.2 (1.6) 1.4 (2.0) 0.2 deterioration
Accelerometer - Total Number of Steps Control 11 19,141 (13284) 23,713 (15088) 4572 Technical problems means
not possible to interpret
Moderate 13 15,947 (20503) 32,445 (26220) 16,498
High 11 14,496 (20785) 21,389 (17503) 6893
Timed Up and Go (seconds) Control 14 19 (10) 25 (18) 7 deterioration
Moderate 13 12 (3) 13 (6) 1 deterioration
High 15 16 (9) 15 (13) −1 improvement
Dual Task Timed Up and Go (seconds) Control 13 23 (10) 28 (17) 5 deterioration
Moderate 10 20 (11) 27 (29) 7 deterioration
High 11 17 (8) 15 (7) −3 improvement
EQ-5D-3L Index Control 13 0.8 (0.2) 0.7 (0.2) 0 unchanged
Moderate 12 0.7 (0.3) 0.8 (0.3) 0.1 improvement
High 16 0.8 (0.2) 0.8 (0.2) 0 unchanged
*score calculated as minutes of exercise multiplied by intensity, for each activity performed
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(95% CI 0.32, 4.5) for moderate and high intensity super-
vision, neither being statistically significant.
Sample size assumptions
For the main trial primary outcome is disability at 12
months. We calculated that a sample size of 184 partici-
pants per group, including 23% attrition (based on previ-
ous studies [6, 39], has 80% power to detect changes in
the disability outcome, DAD, with effect size 0.5 (11
points on a baseline of 70, standard deviation 22, data
from [39, 40]).
The results from this feasibility study broadly sup-
ported our original sample size calculation for the high
intensity supervision group and we have not revised the
original sample size calculation based on these results.
Discussion
We tested the feasibility of evaluating a programme of
therapeutic exercise and activity for people with mild de-
mentia or mild cognitive impairment delivered over one
year, with moderate and high levels of professional
supervision. All criteria for progression to the fully pow-
ered main trial were met. We recruited appropriate par-
ticipants at a sufficient rate, delivery of and adherence to
the intervention, and retention in the study were satis-
factory. Randomisation and data management systems
worked well. There were no unexpected or adverse con-
sequences of the intervention. Completion rates for
baseline and outcome data were satisfactory for most
but not all measures used, but required a carer as a reli-
able informant and blinding of researchers proved un-
feasible. Asking the carer participant to complete some
patient participant scales reduced burden on the patient
participant. The intervention was feasible and safe to de-
liver. We found our sample size estimates for the main
trial to be reasonable.
Recruitment and intervention delivery
Our study was conducted at two sites with different
ways of organising staff to deliver the intervention. The
‘Join Dementia Research’ register proved useful for re-
cruitment, but may have skewed the population to more
educated and younger participants.
Adherence and withdrawal
The adherence rate for the supervised activity and exer-
cise sessions of 66% for the high intensity supervision
version and 100% for the moderate intensity supervision
version is comparable to other studies of this kind which
show a mean adherence rate of 71% [unpublished obser-
vation from Di Lorito C, Bosco A, Booth V, Goldberg S,
Harwood RH, van der Wardt V]. However, mean activity
per week was only 72 min of PrAISED exercises a week,
falling considerably short of the required ‘dose’ of 180
min and WHO recommendations [10]. Therapist train-
ing has been changed for the main trial with a greater
focus on motivation and adherence. Our attrition rate of
Table 4 Standardised effect sizes estimates for moderate and high intensity supervision intervention and missing data
Measures Effect Size for
Moderate Intensity
(95% Confidence
interval)*
Effect Size for
High Intensity
(95% Confidence
interval)*
Missing Data N (%) at
baseline from the 60
recruited participants
Missing Data N (%) at
follow up from the 49
remaining participants
DAD Score 0.03 (−0.7 to 0.8) 0.43 (−0.3 to 1.2) 8/60 (13%) 3/49 (6%)
NEADL Score 0.2 (−0.7 to 1.0) 0.3 (− 0.5 to 1.1) 3/60 (5%) 7/49 (14%)
DEMQoL 0.2 (−0.6 to 1.0) −0.1 (− 0.8 to 0.7) 0/60 (0%) 5/49 (10%)
DEMQoL Proxy 0.4 (−0.4 to 1.1) 0.1 (−0.6 to 0.8) 7/60 (12%) 3/49 (6%)
Berg Balance Scale 0.9 (0.1 to 1.8) 1.0 (0.1 to 1.8) 7/60 (12%) 8/49 (16%)
Falls Efficacy Scale-International −0.8 (−1.7 to − 0.03) −0.5 (−1.3 to 0.3) 2/60 (3%) 9/49 (18%)
IPAQ Physical Activity Score 0.2 (−0.6 to 1.0) 0.6 (−0.2 to 1.4) 3/60 (5%) 7/49 (14%)
HADS Anxiety −0.5 (−1.3 to 0.4) 0.5 (− 0.3 to 1.3) 4/60 (7%) 9/49 (18%)
HADS Depression −0.2 (−1.0 to 0.6) 0.3 (− 0.4 to 1.1) 1/60 (2%) 12/49 (24%)
SHARE Frailty Index −0.7 (−1.4 to 0.1) − 0.2 (− 0.9 to 0.5) 4/60 (7%) 6/49 (12%)
Pedometer-Total Number of Steps 0.4 (−0.4 to 1.2) − 0.2 (− 1.0 to 0.7) 12/60 (20%) 7/49 (14%)
Verbal Fluency - Correct Words 0.5 (−0.3 to 1.2) 0.4 (− 0.3 to 1.1) 1/60 (2%) 4/49 (8%)
Timed Up and Go −0.4 (−1.2 to 0.3) − 0.75 (− 1.5 to 0.00) 0/60 (0%) 7/49 (14%)
Dual Task Timed Up and Go 0.3 (−0.5 to 1.2) − 0.4 (− 1.2 to 0.4) 5/60 (8%) 13/49 (27%)
EQ-5D-3L Index 1.4 (0.5 to 2.2) 0.3 (−0.4 to 1.0) 1/60 (2%) 8/49 (16%)
Note: 0–0.3 = trivial; 0.3–0.5 = small; 0.5–0.8 =moderate; > 0.8 = large
*Positive values show an effect in favour of intervention group
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18% was acceptable compared to similar studies (23%
for FiNALEX [6]; 9% for Wesson [21]).
Supervision intensity required to enable engagement
The standardised effect size estimates for the primary and
some intermediate outcome measures (whilst difficult to
interpret due to small sample size) suggest the interven-
tion, delivered with a high level of supervision, could feas-
ibly show a positive effect at 12month outcomes in a fully
powered comparison (in other words, the intervention is
not shown to be futile). The PrAISED intervention re-
quired patient participants to complete 3 h of PrAISED
exercises a week for 12months, but differed according to
the amount of professional contact they received. Of the
two intervention groups, the greater effect size was seen
with the high intensity supervision group. Measured ad-
herence was not different between these groups, but these
data are difficult to collect, not least because the difference
between an ‘exercise’ and an ‘activity’ can be difficult to
determine, and therapists reported that some participants
chose to do ‘activities’ over ‘exercises’ as time went by.
Care may be enhanced in the therapy arms through the
interactions between participant and therapist (such as if
the therapist referred the patient participant to services
for a problem not related to the intervention [41]). We
cannot be sure whether it was the ‘social’ contact or the
therapy programme that changed outcomes, however, in
complex intervention trials all elements are typically con-
sidered together. It was not feasibly to have a sham con-
trol and it is common practice to have a ‘usual care’
control arm [6, 9, 21] for activity and exercise interven-
tions for this patient group. Our research suggests partici-
pants are less likely to do the exercise without human
contact (through supervision or support from carers) [42].
Collection of blinded data
Unblinded trials can result in bias [43], however, we
found blinding was impossible to maintain in practice.
Issues of bias in outcome data collection need to be ad-
dressed through specific anti research bias training,
which we have put in place for the main trial.
Many people with dementia live alone in the commu-
nity and some do not have any family carers. We wanted
to be inclusive in our recruitment, but found we could
not complete primary outcome data with this policy and
will restrict our inclusion criteria for the main trial to
those with a carer willing to take part.
The DAD as a primary outcome measure has been
used before in similar trials; is recommended [44] and
was well completed when a carer was available. How-
ever, the DAD did show a ceiling effect at baseline and
outcome; potentially reducing the chances of demon-
strating effectiveness. Better ADL outcome measures for
people with early dementia are needed. Measurement of
physical activity using accelerometers was inaccurate
due to technical difficulties, which were resolved during
the feasibility trial and which has informed researcher
training. We selected the best performing accelerometer
for the main trial (Misfit Shine 2). Carer participants
found the IPAQ difficult to complete and we have chan-
ged it to the Longitudinal Aging Study Amsterdam phys-
ical activity questionnaire for the main trial [45]. An
independent CTU managed the data and undertook stat-
istical analysis blind to intervention group. Some scales
had high levels of missing data resulting in some being
dropped or changed and instructions on completion be-
ing clarified for the planned main trial.
Unexpected or adverse outcomes
There were no serious adverse events related to the inter-
vention, suggesting the intervention does not cause harm.
In a trial where one group has considerably more contact
than the other, there is the problem of differential report-
ing of adverse events, and comparing rates of adverse
events in different groups is impossible to interpret. We
have embedded safety parameter variables (mortality, hos-
pitalisation, falls, injury) in the outcome dataset, which is
collected independently of contact with therapists deliver-
ing the clinical intervention. This approach was agreed by
our Data Monitoring Committee.
Sample size assumptions
Our sample size assumptions are shown to be
reasonable.
Conclusions
We have tested the feasibility of a multisite randomised
controlled trial using a three arm study and found, that
a larger trial is feasible with some adjustments to
methods. The adjustments to the trial protocol identified
in this study demonstrate the importance of conducting
a feasibility study prior to full trial.
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